Bacterial Vaginosis and the Vaginal Microbiome

Overview

Bacterial vaginosis (BV) is the most common vaginal condition in women of reproductive age, affecting an estimated 29% of women globally. Unlike a classic infection caused by a single pathogen, BV represents a polymicrobial shift in the vaginal ecosystem -- a transition from a protective, Lactobacillus-dominated community to a diverse consortium of anaerobic bacteria. Symptoms may include thin grayish-white discharge, a characteristic fishy odor, and vaginal irritation, though roughly half of affected women are asymptomatic.

BV is clinically significant beyond its immediate symptoms. It has been associated with increased susceptibility to sexually transmitted infections including HIV, adverse pregnancy outcomes such as preterm birth, and higher risk of pelvic inflammatory disease.^[1] The frustratingly high recurrence rate following standard antibiotic therapy -- approaching 50% within twelve months -- has driven intense interest in understanding and restoring the vaginal microbiome as a more durable treatment approach.^[2]

The vaginal microbiome is unique among human body sites: in health, it is characterized not by high diversity but by the dominance of a single protective genus. This distinctive ecology makes BV one of the conditions most clearly defined by microbiome disruption, and positions microbiome restoration as a particularly logical therapeutic strategy.^[3]

Key Takeaways

• A healthy vaginal microbiome is characterized by Lactobacillus dominance, which maintains protective acidity and inhibits pathogens^[3]
• BV represents a polymicrobial shift to anaerobic biofilm communities resistant to standard antibiotic therapy^[4]
• Recurrence rates approach 50% within 12 months of treatment, highlighting the need for microbiome-restorative approaches^[2]
• Intravaginal Lactobacillus crispatus after antibiotic treatment has shown promise for reducing BV recurrence in a landmark randomized trial^[5]
• Host-microbe interactions, including immune and epithelial factors, play important roles in BV susceptibility beyond bacterial composition alone^[6]

The Microbiome Connection

Vaginal Community State Types

The healthy vaginal microbiome is unique among human body sites in its low diversity. Ravel and colleagues identified five community state types (CSTs) in reproductive-age women, four of which are dominated by a single Lactobacillus species: L. crispatus (CST I), L. gasseri (CST II), L. iners (CST III), or L. jensenii (CST V).^[3] The fifth type (CST IV) is characterized by higher diversity and lower Lactobacillus abundance, and is more commonly associated with BV. These Lactobacillus species produce lactic acid that maintains vaginal pH below 4.5, hydrogen peroxide, and bacteriocins that collectively inhibit the growth of pathogenic organisms.^[7]

The BV Transition and Biofilm Formation

In BV, this protective Lactobacillus dominance collapses and is replaced by a diverse polymicrobial community featuring Gardnerella vaginalis, Atopobium vaginae, Prevotella species, and other anaerobes.^[1] These organisms form adherent biofilms on the vaginal epithelium that are highly resistant to antibiotic penetration, which helps explain the condition's tendency to recur.^[4] The transition involves rising vaginal pH, loss of lactic acid production, and increased production of biogenic amines that create the characteristic odor.

Muzny et al. described BV pathogenesis as involving complex host-microbe interactions, noting that individual differences in vaginal epithelial cell receptor expression, immune responses, and hormonal factors all influence susceptibility beyond bacterial composition alone.^[6] This host-interaction model helps explain why some women with polymicrobial vaginal communities remain asymptomatic while others develop clinical BV.

Triggers and Risk Factors

While the precise triggers for the Lactobacillus-to-BV transition remain debated, factors such as antibiotic use, douching, new sexual partners, and hormonal changes have all been implicated. The biofilm structure of BV communities means that even when antibiotics temporarily reduce symptoms, the underlying dysbiotic architecture often persists and facilitates relapse.^[2]

Key Microorganisms

Lactobacillus crispatus

• Impact: The most protective vaginal Lactobacillus species; its dominance (CST I) is associated with the lowest BV risk
• Function: Produces both D- and L-lactic acid isomers, maintaining the strongest acidic environment among vaginal Lactobacillus species; intravaginal supplementation after antibiotics reduced BV recurrence in a randomized trial^[5]

Gardnerella vaginalis

• Impact: The primary biofilm-forming organism in BV; initiates and maintains the polymicrobial dysbiotic community
• Function: Produces sialidase and vaginolysin that damage vaginal epithelial cells, and forms adherent biofilms that resist antibiotic penetration and provide a scaffold for other BV-associated anaerobes^[4]

Lactobacillus iners

• Impact: A transitional species that may be present in both health and BV; considered less protective than L. crispatus
• Function: Produces only L-lactic acid (not D-lactic acid), resulting in weaker pathogen inhibition; may not adequately prevent the transition to BV in some women^[3]

Atopobium vaginae

• Impact: Strongly associated with BV and often resistant to metronidazole; its persistence may contribute to treatment failure
• Function: Participates in BV biofilm formation alongside Gardnerella and produces metabolites that sustain the elevated-pH anaerobic environment^[1]

Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14

• Impact: The most studied oral probiotic combination for vaginal health; some evidence for BV recurrence reduction
• Function: May reach the vaginal tract after oral administration and support Lactobacillus restoration through competitive exclusion, immune modulation, and bacteriocin production^[8]

Microbiome-Based Management Strategies

Intravaginal Lactobacillus Restoration

The Lactin-V trial demonstrated that vaginally applied Lactobacillus crispatus CTV-05 administered after standard metronidazole treatment reduced BV recurrence at 12 weeks (30% vs. 45% in placebo), providing the strongest evidence to date for probiotic-based BV prevention.^[5] This approach directly addresses the underlying microbial imbalance rather than solely targeting pathogenic bacteria. Evidence Level: Moderate to Strong

Oral Probiotic Supplementation

Oral probiotics containing Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 have been investigated in smaller trials with mixed but generally encouraging results.^[8][7] These strains may support vaginal health through lactic acid production, pathogen inhibition, and immune modulation, though they may not colonize the vaginal environment as effectively as native vaginal Lactobacillus species applied topically. Evidence Level: Preliminary to Moderate

Lifestyle and Hygiene Practices

Avoiding douching preserves the natural acidic environment, while cotton underwear and breathable fabrics may reduce conditions favorable to anaerobic overgrowth. Hormonal factors, particularly estrogen levels, strongly influence vaginal Lactobacillus abundance, which is relevant for women on hormonal contraceptives or approaching menopause. Some evidence suggests that a diet rich in prebiotic fiber may indirectly support vaginal Lactobacillus populations through systemic metabolic effects. Evidence Level: Preliminary (dietary); Moderate (douching avoidance)

Post-Antibiotic Microbiome Support

Given that antibiotics effectively treat acute BV episodes but often fail to prevent recurrence, combining standard antibiotic therapy with subsequent probiotic restoration represents a logical sequential approach. The Lactin-V trial model -- antibiotics followed by probiotic maintenance -- may become a standard of care as additional evidence accumulates.^[5] Evidence Level: Moderate

All BV management strategies should be discussed with a healthcare provider, particularly during pregnancy when BV carries additional risks for adverse outcomes.

Future Directions

The field of BV microbiome research is advancing toward more effective and durable treatments. Live biotherapeutic products (LBPs) containing optimized strains of L. crispatus or defined multi-species consortia are in clinical development, with the goal of achieving lasting vaginal recolonization after antibiotic treatment. Researchers are also investigating biofilm-disrupting agents that could be used in combination with antibiotics to address the biofilm sanctuary that drives recurrence.

Personalized approaches based on an individual's vaginal community state type may eventually guide treatment selection, as women with different baseline microbiome profiles may respond differently to various interventions. The role of sexual transmission in BV maintenance is also receiving renewed attention, with trials exploring concurrent partner treatment as a strategy to reduce reinfection. As these approaches mature, the management of BV may shift from repeated antibiotic courses toward durable microbiome restoration as a primary therapeutic goal.